title: Multifocal electroretinogram findings after intravitreal bevacizumab injection in choroidal neovascularization of age-related macular degeneration.
abstract: OBJECTIVE
  To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography (OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD).
  
  
  METHODS
  Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG.
  
  
  RESULTS
  The BCVA improved, while central macular thickness and total macular volume in OCT decreased after intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal bevacizumab injection.
  
  
  CONCLUSIONS
  There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bevacizumab injection.
authors.affiliation: Department of Ophthalmology, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Joo Youn
authors.initials: JY
authors.lastname: Park
authors.forename: Seung Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Tae Kwann
authors.initials: TK
authors.lastname: Park
authors.forename: Young-Hoon
authors.initials: YH
authors.lastname: Ohn
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D004596:Electroretinography / Q000379:methods*; D005139:Eyeglasses; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D008875:Middle Aged; D012160:Retina / Q000187:drug effects / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab